Exercise is known to increase blood flow to the brain (Herholz et al., [@b22]) and the release of several neurotrophic factors (Klintsova et al., [@b27]; Leak et al., [@b37]; Voss et al., [@b64]), but relatively few studies have examined the cellular basis for improvement of brain function by exercise. Increased neuronal proliferation in the hippocampus of adult mice (Holmes et al., [@b23]; Olah et al., [@b43]) was found, but exercise did not promote neurogenesis in the motor, visual, or cingulate cortices (Ehninger and Kempermann, [@b16]). However, exercise did have an effect on neocortical gliogenesis. In wheel-running mice, there was an increase in layer 1 microglia in the motor cortex (Ehninger and Kempermann, [@b16]) and a decrease of new cells that coexpressed the proteoglycan, NG2, and the astrocyte marker, s100β, in the visual cortex (Ehninger 2011). And in adult mice with access to running wheels, NG2^+^ cell proliferation was reduced but NG2^+^ cell differentiation into mature oligodendrocytes was increased (Simon et al., [@b55]).

NG2^+^ cells are the most abundant new cell type in the brains of adult rodents. Although early studies considered these cells to be multipotential neural and glial progenitor cells (Raff et al., 1983; Stallcup, [@b56]), the conclusion of recent cell fate studies in mice is that NG2^+^ cells, in the form of polydendrocytes (Nishiyama et al., [@b42]), are almost exclusively oligodendrocyte precursor cells (Rivers et al., [@b54]; Dimou et al., [@b11]; Kang et al., [@b26]; Hughes et al., [@b24]). However, perivascular brain pericytes also express NG2 and, because they are angiogenic during brain development (Virgintino et al., [@b63]), injury (Diaz-Flores et al., [@b10]; Dore-Duffy and Cleary, [@b13]), or pathology (Helfer et al., [@b21]), it seems reasonable that they might be active during angiogenesis that results from exercise (Isaacs et al., [@b25]; Swain et al., [@b57]; Ding et al., [@b12]; Rhyu et al., [@b53]).

To date, there have been no studies of adult born NG2^+^ cells in the monkey cerebral cortex. The current study examines new NG2^+^ cells over several time intervals including two time periods following experimental exercise. In addition, we also examined the expression of other glial and neuronal markers of adult born cells. We focused on two goals: 1) categorizing the major phenotypes and relative proportions of adult born NG2 cells in the cerebral cortex, and 2) determining if any cell type is responsive to one or more variables of an experimental exercise protocol.

Materials and methods
=====================

Subjects
--------

We used six adult female *Macaca mulatta* (ages ∼5.5--7.0 years) and 24 adult female *Macaca fascicularis* (ages 10--17 years) for these experiments. The *M. fascicularis* monkeys were part of a larger study of the effects of exercise on the brain (Rhyu et al., [@b53]; Kohler et al., [@b29]). The monkeys were housed in pens approximately 2 m by 4.5 m by 3.3 m high within a social living group of 2--3 similar aged pen mates, or in individual cages. They were fed Purina Monkey Chow (no. 5045; Ralston-Purina, St. Louis, MO) once daily. Animals living in pens had both natural and artificial lighting, making the light/dark cycle equivalent to natural day length in the summer months and 0700 hours to 1900 hours in the winter months. Animals living in cages had lights on from 0700 hours to 1900 hours. All animal care and use and tissue procedures were conducted in accord with protocols approved by the Institutional Animal Care and Use Committees of the University of Pittsburgh and the University of Illinois and in accordance with NIH standards and guidelines.

Experimental design
-------------------

The thymidine analog bromodeoxyuridine (BrdU) was administered by intraperitoneal injection in six *M. mulatta* monkeys as a single dose (100 mg/kg) under light sedation to study phenotype expression of BrdU-marked cells over short postinjection survivals (Fig. [1](#fig01){ref-type="fig"}A). Two of these monkeys were sacrificed at 48 hours, two were sacrificed at 2 weeks, and two were sacrificed at 6 weeks after injections. The motor cortex from one 2-week monkey was not usable for immunohistochemistry and so this tissue was dropped from the study. Throughout the article this group of five monkeys will be referred to as the short survival group. Twenty-four *M. fascicularis* monkeys from an exercise study (Rhyu et al., [@b53]) were given 10 weekly injections of BrdU (75 mg/kg) and sacrificed at 15 weeks (16 monkeys) or 27 weeks (8 monkeys) after initial BrdU injections to study the effects of age, exercise, postexercise inactivity, and longer survivals on the expression of BrdU and other antibody markers. Figure [1](#fig01){ref-type="fig"}B summarizes the time line and experimental groupings of the exercise experiment. The monkeys were evenly divided into older (15--17 years) and younger (10--12 years) adults. Sixteen monkeys were trained to run on a treadmill 5 days a week for 9 weeks until they attained individual running speeds of 80% maximal aerobic power. These monkeys continued to run at optimal rates for an additional 15 weeks. Eight sedentary control monkeys sat on stationary treadmills during treadmill running sessions. Eight of the 16 running monkeys rested for an additional 12 weeks after exercise before they were killed. The monkeys of the experimental exercise study are referred to throughout the paper as the long survival monkeys.

![Timeline diagrams of monkey groups. A: Monkeys that received a single BrdU injection and survived short time intervals before perfusion (down arrows). B: Runner and sedentary control monkeys that received 10 weekly BrdU injections and survived 5 or 17 weeks after the injection period.](cne0523-0849-f1){#fig01}

Perfusion and tissue preparation
--------------------------------

All monkeys were deeply anesthetized with sodium pentobarbital (30 mg/kg, i.v.) and perfused intracardially with physiological saline containing heparin (5000 U/l) and sodium nitrite (20 g/l) followed by cold 4% paraformaldehyde in PBS. The brain was removed and postfixed for 4 hours in cold 4% paraformaldehyde in phosphate-buffered saline (PBS) followed by immersion in 20% glycerol in PBS. The brains were cut into coronal blocks and placed in 30% sucrose in Tris-buffered saline (TBS) until sinking (∼4 weeks with weekly change of solutions). Brain blocks containing the precentral gyrus (14 mm posterior to 7 mm anterior to the anterior commissure; Martin and Bowden, [@b40]) were covered with tissue freezing media, frozen at --19°C, and sectioned coronally at a thickness of 40 μm. Sections were collected in multiwell plates containing cryoprotectant (30% sucrose, 30% ethylene glycol in TBS) and stored at --20°C.

Fluorescence immunohistochemistry (IHC)
---------------------------------------

Free-floating sections of cortical tissue through the precentral gyrus and medial wall of the hemisphere to the cingulate fundus were processed for fluorescence IHC. Series of sections from every animal were batch-processed for combinations of antibody and lectin markers (Table[1](#tbl1){ref-type="table"}). Control sections in each experiment underwent the same processing steps but were not incubated in primary antibodies. Tissue sections processed for BrdU and NG2 antibodies were washed in TBS then 0.6% H~2~O~2~ before incubating overnight at 4°C in NG2 antibody alone or in combination with PDGFrβ antibody (see Table[1](#tbl1){ref-type="table"} for abbreviations). After washing in a solution of TBS and 0.5% Triton X in 3% normal donkey serum (TBS-TDS) for 1 hour at room temperature, sections were incubated in solutions of biotin-donkey-antimouse secondary antibody, ABC reagent, and tyramide (TSA)-Cy5 conjugate in amplification diluent (1:50 for 5 minutes). In tissue batches processed for both PDGFrβ and NG2 primary antibodies, fluorescein tagged donkey-antirabbit secondary antibody was added to the conjugated biotin secondary antibody solution. Following the first TSA amplification, sections were washed in TBS, then 0.6% H~2~O~2~, and then incubated in anti-fluorescein-horseradish peroxidase (HRP) conjugate for 30 minutes before the second TSA (TSA-Cy3). Following a TBS wash, sections were pretreated for BrdU processing in aqueous 2 N HCl for 30 minutes at 47°C followed by a neutralizing solution of 0.1 M boric acid in TBS (pH = 8.6) for 10 minutes at room temperature. Sections processed for collagen IV antibody were washed and incubated in a solution of pepsin (1 mg/ml) in .2 M HCl. After a 5-minute wash in TBS, nonspecific labeling was blocked by 0.5% Triton X and 3% normal donkey serum in TBS (TBS-NDS) for 1 hour at room temperature. Sections were incubated overnight at 4°C in anti-BrdU primary antibody, avidin blocking solution, and in some batches a second primary antibody. Following TBS-TDS and biotin blocking solution washes, sections were incubated in biotinylated donkey-antirat secondary antibody that was combined in some batches with other Cy3-conjugated secondary antibodies. Biotinylated antibody was visualized with Cy-2 conjugated streptavidin. Following TBS washes, some sections were incubated for 10 minutes at room temperature in *Lycopersicon esculentum* (tomato) lectin conjugated with Dylite 594. Sections were mounted on slides using Prolong Gold antifade mounting media (Molecular Probes, Eugene, OR).

###### 

Primary Antibodies Used for Immunohistochemistry

  Antibody                                                           Immunogen                                                                                    Manufacturer catalog \#, host species, mono- vs. polyclonal, and RRID \#     Dilution used
  ------------------------------------------------------------------ -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------
  Bromodeoxyuridine (BrdU)                                           BrdU incorporated into DNA                                                                   Accurate Chemical - AbD Serotec \#T0030, rat monoclonal, RRID \#AB609566     1:500
  Calbindin (Cb)                                                     Recombinant mouse calbindin                                                                  Chemicon-Millipore \#AB1778, rabbit polyclonal, RRID \#AB 2068348            1:200
  Calretinin (Cr)                                                    Recombinant rat calretinin                                                                   Chemicon-Millipore \#AB5054, rabbit polyclonal, RRID \#AB 2068506            1:500
  Collagen IV (COL IV)                                               Collagen Type IV extracted and purified from mouse tumor                                     Chemicon-Millipore \#AB756P, rabbit polyclonal, RRID \#AB2276457             1:300
  Doublecortin (DCx)                                                 Synthetic peptide to human doublecortin corresponding to aa CysYLPLSLDDSD SLGDSM-free acid   Cell Signaling Technology \#4604x, rabbit polyclonal, RRID \# AB561007       1:400
  Gamma amino butyric acid (GABA)                                    γ-aminobutyric acid (GABA) conjugated to BSA                                                 Sigma-Aldridge \#A2052, rabbit polyclonal, RRID \#AB477652                   1:2000
  Glia fibrillary acidic protein (GFAP)                              Purified bovine GFAP                                                                         Chemicon-Millipore \#AB5804, Rabbit polyclonal, RRID \#AB2109645             1:1600
  Iba1 - (Ionized calcium binding adaptor molecule 1)                Synthetic peptide corresponding to C-terminus aa NA^′^-PTGPPAKKAISELP-C^′^                   Wako Chemicals USA, Inc. \#019-19741, rabbit polyclonal, RRID \#AB839504     1:200
  Neural-glial antibody 2 (NG2) 9.2.27                               Human M14 melanoma cell extract                                                              Gift from Dr. Ralph Reisfeld, Scripps Research Institute, mouse monoclonal   1:1500
  Neuron specific nuclear protein (NeuN)                             Purified cell nuclei from mouse brain                                                        Chemicon-Millipore \#AB377, mouse monoclonal, RRID \# AB94966                1:500
  Oligodendrocyte transcription factor 2 (Olig2) Rabbit anti-human   Synthetic peptide in portion of C-terminus of Human Olig2, aa 236-285                        IBL-America \#18953, rabbit polyclonal, RRID \# AB494617                     1:100
  Platelet derived growth factor receptorß (PDGFrß)                  Synthetic peptide, aa 1086-1106 from C-terminus of human PDGFrß                              Epitomics -ABCAM \#32570, rabbit monoclonal, RRID\# AB777165.                1:400
  S100ß                                                              recombinant S-100ß                                                                           Swant 36 (discontinued),r bovine polyclonal                                  1:4000

Antibody characterization
-------------------------

Rat anti-BrdU antibody (clone BU1/75 \[ICR1\]), NeuN antibody for mature neurons, and DCx antibody for immature neurons were used on test sections through the motor cortex with sections from the hippocampus where new, immature, and mature neurons were known to exist (Kohler et al., [@b29]). BrdU^-^/NeuN^+^ expressing cells were pyramid-shaped or interneuron-like (determined by shape, size, and occasional colabeling with Cr antibody) and no labeling of glia or other cell types was observed. Manufacturer\'s data sheets indicate that NeuN antibody recognized 2--3 bands in the 46--48 kDa range and possibly another band at approximately western blot 66 kDa. Doublecortin antibody to the microtubule associated protein was characterized by western blot 45 kDa.

Calbindin (28 kDa) and calretinin (29 kDa) antibodies detect similar but distinct calcium binding proteins in interneurons. In our material, cells expressing these antibodies were predominantly bipolar and similar in size and morphology to Cr and Cb cell types described by others (Gabbott and Bacon, [@b18]; Barinka and Druga, [@b1]). Antibody to GABA also labeled cells that were similar in morphology, size, and location near large pyramidal cells to Cr-labeled interneurons. No other cell types were detected using these antibodies.

Iba antibody for microglia and s100β and GFAP antibodies for astrocytes were used to look for colabeling with NG2. Cells labeled with these antibodies were typical of microglia and astrocytes in the monkey cerebral cortex shown in a similar study by Koketsu et al. ([@b30]). No other cell types were detected using these antibodies.

Col IV antibody recognizes the 139 kDa protein from mouse tumor tissue. Col IV is the collagen of basement membranes of brain pericytes. In our material, the antibody colocalized with NG2 labeling along vascular walls and defined both the luminal and abluminal membranes of NG2^+^ cells. No other labeling with Col IV was observed.

Olig2 is a transcription factor for oligodendrocyte precursor cells that is localized in the nucleus but translocates to the cytoplasm in cells responding to brain injury (Cassiani-Ingoni et al., [@b6]). Olig2 colocalizes with NG2 in these cells (Ligon et al., [@b39]). In our material, Olig2 antibody only labeled nuclei of cells that were NG2^+^.

We screened six NG2 antibodies in comparative IHC batches with rat and monkey brain sections. One NG2 antibody was Chemicon\'s (Temecula, CA) rabbit polyclonal (AB5320), and five antibodies, three rabbit polyclonals, and two mouse monoclonals were provided by Dr. William Stallcup. Only the mouse monoclonal antibody 9.2.27 demonstrated conclusively the presence of NG2^+^ cells in monkey (but not in rat), whereas all polyclonal antibodies labeled NG2^+^ cells in rat neocortex. NG2 polyclonal antibody 9.2.27 reacts with the core protein of chondroitin sulfate proteoglycan developed against human melanoma cells (Bumol et al., [@b5]). To our knowledge, this is the first reported study of NG2^+^ cells in the brains of monkeys using this antibody.

PDGFrβ antibody recognizes the 190 kDa human platelet-derived growth factor, tyrosine kinase receptor. According to the product data sheet, this antibody does not crossreact with other CSF-1/PDGF receptor family members. In our material, PDGFrβ reacted with portions of all NG2^+^ cells, but PDGFrβ and NG2 antibody expression was not completely coincidental. No other cells were labeled with PDGFrβ antibody.

Quantification of new cells
---------------------------

Tissue sections from each animal were selected from randomly chosen wells for batch IHC. In most cases, the primary motor cortex from the cingulate to the central sulcus was dissected from the entire section to provide optimal staining of the greatest number of sections in the least amount of antibody. Two large IHC batches consisted of sections from the 24 long survival monkeys that stained for BrdU, NeuN, and Cr, or BrdU, NG2, and PDGFrβ. Smaller IHC batches combined sections from short and long survival monkeys so that batch effects of processing would be the same for both monkey groups. These batches were stained for BrdU, NG2, and either Cr, Olig2, or PDGFrβ. All short survival monkeys and all but one monkey (younger adult, control) from the long survival monkeys were sampled for counts of new NG2^+^ cell phenotypes, and all monkeys from both groups were sampled for new Cr^+^ cell counts. Counts of new cells stained for Olig2 and NG2 were made from four short survival monkeys and eight long survival, younger monkeys. Counts of new PDGFrβ^+^ cells were discontinued when it appeared that the antibody colabeled NG2^+^ cells. Small IHC batches in 3--5 long survival monkeys were used to search for colabeling between antibodies to BrdU and DCx; BrdU, Col IV, and NG2; s100β and NG2; and Iba1 and NG2. No cells were counted in sections from these small IHC batches. In an initial count of BrdU^+^, Cr^+^, and NeuN^+^ cells in 24 long survival monkeys, counts of 100 labeled cells / 3 sections/animal were made from three coronal sections through the precentral gyrus according to the \"rare event\" sampling protocol (Mouton, [@b41]). In subsequent IHC batches for Cr and other antibodies, fewer cells were counted (30--75/animal/IHC batch) from 3--5 sections per monkey. Small IHC batches were processed for GABA antibody to provide a comparison to Cr^+^ cells. However, because cells labeled with GABA antibody might result from passive uptake rather than expression of the protein (Dayer et al., [@b9]), and because GABA antibody preparations are noisy compared to Cr antibody preparations, GABA^+^ cells were not counted. Section slides were masked to obscure animal identities before labeled cells were imaged and counted using a Leica SP2 Confocal microscope (63× oil objective; 400× total magnification). The surface and white matter of the motor cortex of each section were outlined with a marker on the backs of the slides. After centering a slide, counting began by a zig-zag scan through the neocortex using a joystick to move the slide. Every new BrdU^+^ cell was imaged and then recorded on an Excel spreadsheet. All images were reviewed \"off-scope\" to correct errors in data entry. Special images of cells with four labels were made using a Zeiss LSM 710 confocal microscope. Images were processed for publication using Leica LAF, Zeiss Zen, NIH ImageJ, and Canvas 8 and 11 softwares. Counts of new NG2^+^ cell phenotypes of different morphologies, immunoreactivities, and relationships to other structures were totaled from IHC batches of short and long survival monkey tissue and estimates of phenotype proportions to total BrdU+ cells were made using binomial regression modeling. *P*-values were calculated for comparisons between groups of the exercise experiment using log odds ratios resulting from the binomial regression analysis.

Results
=======

It was clear from the first viewing of NG2^+^ cells in the monkey motor cortex that these cells types displayed a variety of forms other than the polydendritic one that is used to commonly identify these cells (Nishiyama et al., [@b42]). In Figures [2](#fig02){ref-type="fig"}--[4](#fig04){ref-type="fig"}, we illustrate NG2^+^ cells in a progression of cell phenotypes from simple to complex. To determine if any of these cell types were responsive to the conditions of the study, we classified and counted new NG2^+^ cells by their association with presumed vascular elements (perivascular, nonperivascular), the number and complexity of their cell processes (not multibranched, multibranched), and their colabeling with neuronal and glial antibodies. Counts of closely paired BrdU^+^/NG2^+^ cells were also made. In addition, we detected and counted a small proportion of new cells that expressed calretinin. We will first describe new cell phenotypes and then the proportions of new Cr^+^ cells and NG2^+^ cell phenotypes in short and long survival monkeys.

![New NG2 cells classified as pericytes (A--D) and Elu cells (E--J). A1,2: New pericytes embedded in the walls of NG2-rich vessels. Cell processes of these cells are confined to the vessel walls. An unlabeled pericyte profile can be seen below the labeled cell in 1. Asterisks mark vessel lumens in this and other images of the figure. B: A new pericyte merges with the vessel wall. Longitudinal and transverse filaments in vessel wall typical of pericytes are highlighted by NG2 and PDGFrβ antibodies. C: New pericyte cell on vessel surface. PDGFrβ^+^ label is concentrated along the vessel lumen and transverse pericyte processes are visible. D: New pericyte on vessel surface lies internal to Col IV, a component of the basement membrane. E: Elu cell protruding into a small vascular space. The endothelial wall opposite the cell is labeled by tomato lectin. The vascular space was continuous with a larger, bifurcating vessel that would be invisible except for labeling of the vessel wall by tomato lectin. The vessel lumen is marked with an asterisk. F: Two Elu cells seen in three optical slices. Channels that make up the middle slice appear in the lower tier of images. The upper cell bulges into a small vascular space that is marked with tomato lectin. G: A pair of Elu cells labeled with Olig2. A small, branching process extends upward from the right cell. H--J: Three projection slices of an Elu cell at the branch point of a small vessel from a larger one (asterisk in I). Cell processes (arrowheads in H, J2) labeled with NG2 and PDGFrβ antibodies extend transversely and longitudinally along the vessel wall and into the brain parenchyma. PDGFrβ label was most concentrated next to the endothelial cell wall that is labeled with tomato lectin. Note that the nucleus of the cell is external to the endothelial wall. Three of four channels that make up merged images in H, I4, and J are shown in I1-3. J1, 3 are orthogonal images of J2. Scale bars = 10 μm.](cne0523-0849-f2){#fig02}

![Polydendrocytes (Pld) and polydendritic perivascular cells (Pldv) are characterized by multiple, complex branches. A: A pair of new Pld cells with closely paired nuclei indicating recent cell division. PDGFrβ labeling was seen near the cell body and in one process of the lower cell but these cells were not perivascular. B: Two Pldv cells with thick, branching dendrites enclosing a small vascular space (asterisk). Only the lower cell is new born and sparsely labeled with Olig2. C,D: A new Pldv cell partially enclosing a small vessel (C4, asterisk; arrowheads in C3 and orthogonal slices D1,2). The projection stack of sections in D3 shows multiple branching processes of the cell that obscure the vessel. E,F: A pair of Pldv cells and adjacent vessel shown in two slice planes. The vessel lumen (asterisks) can be seen in single sections (E1,F1) but is obscured by the processes of the cell in maximum projection stacks (E2,F2). The approximate plane of section for E1 can be seen as line in F1. G--I: A Pldv cell with unstained passage (arrow) in a cell process extending to the left and clefts (arrowheads) that are continuous with adjacent vessel. G--H: Two optical slices through the cell showing NG2 and combined BrdU and NG2 channels. I: A z projection stack of all optical slices through the cell. The arrowhead points to a cleft that opens into the lumen of the vessel seen in H1. Scale bars = 10 μm.](cne0523-0849-f3){#fig03}

![Two NG2^+^ cells showing vacuoles and tube-like passages within processes labeled with PDGFrβ antibody. A: A merged, projection stack image of the cells (1,2). Two of many NG2^+^- rich processes that have little or no PDGFrβ^+^ are marked with arrows (also in B3). Two processes are densely colabeled with PDGFrβ^+^ and contain tube-like passages (single and double arrowheads; also in B1,4; D3) that extend the length of the processes and end in large expansions (asterisks). The large, central process appears to be a complex of processes from cells 1 and 2, whereas the shorter, horizontal process arises from cell 1 alone. B1--4: Single xy slices, showing a central passage (arrowheads) extending between the perinuclear regions of cells 1 and 2. Note the budding of a tube-like passage in the horizontal process in B1. Smaller vacuoles are seen in B2. C: Side view reconstruction of the two cells showing the two PDGFrβ-labeled processes (other processes were digitally removed). The open arrowhead shows an alignment artifact (also seen in D1--3) between the two stacks that make up images A and C. D1--3: Single yz slices showing the central (arrowhead) and horizontal (double arrowheads) passages seen in A. The central tube ends in an expansion (asterisks). The inset in 2 shows the expansion in optical slices that are adjacent to the one in 2 (a, xy; b, yz; c, xz slice planes). Note that the expansion is enclosed within the process. Scale bars = 10 μm.](cne0523-0849-f4){#fig04}

NG2^+^ cell phenotypes
----------------------

New, NG2^+^ cells that merged with vessel walls and that lacked cell processes were classified as pericyte (Per) cells. We included cells with prominent BrdU^+^ nuclei embedded in NG2^+^-rich blood vessel walls (Fig. [2](#fig02){ref-type="fig"}A) and cells on the abluminal surfaces of vessels (Fig. [2](#fig02){ref-type="fig"}B--D). In some of the latter cell types, the cell membrane external to the nucleus was poorly labeled with NG2 (Fig. [2](#fig02){ref-type="fig"}C) but the cell\'s basement membrane, a characteristic of pericytes (Krueger and Bechmann, [@b35]), could be identified by the presence of collagen IV external to the nucleus (2D). Furthermore, PDGFrβ, which is also characteristic of pericytes (Winkler et al., [@b65]), was found in these cells concentrated along the luminal membrane (Fig. [2](#fig02){ref-type="fig"}B,C). NG2 and PDGFrβ antibodies highlighted pericyte processes and longitudinal and transverse filaments of vessel walls (Fig. [2](#fig02){ref-type="fig"}A--C). Per cells were found in monkeys that survived 2 days following a single BrdU injection and in animals that survived 27 weeks after the initial injection of 10 weekly BrdU injections.

A second type of BrdU^+^/NG2^+^ cell lacked clearly defined cell processes (Fig. [2](#fig02){ref-type="fig"}E,F) or had few, simply branched ones that followed vessel walls or extended short distances into the parenchyma (Fig. [2](#fig02){ref-type="fig"}G--J). Because of their simple form and association with vascular elements, these cells were counted with Per cells as a single category. The cell body of these cells protruded into the small vessels where they were located and cytoplasmic extensions from the cells partially enclosed vascular spaces. In some examples, we confirmed the presence of vessel walls using tomato lectin (Fig. [2](#fig02){ref-type="fig"}E--J) (Porter et al., [@b50]). We called these NG2^+^ cells early lumen (Elu) cells because they appeared at sites of small vessel branches (Fig. [2](#fig02){ref-type="fig"}I). Expression of PDGFrβ in Elu cells was concentrated along the vessel wall, but other parts of the cell, including processes, displayed patches of PDGFrβ marker (Fig. [2](#fig02){ref-type="fig"}H,J).

Cells with multiple branched processes characterized a common type of BrdU^+^/NG2^+^ cell. In rodents, these cells are identified as polydendrocytes (Nishiyama et al., [@b42]) and we adopted this terminology. In the macaque, the characteristic processes of polydendritic (Pld) cells are irregular, tortuous branches radiating as far as 35 μm from the cell body and frequently intertwining (Fig. [3](#fig03){ref-type="fig"}). The processes varied. In some cells they were thin and relatively uniform in diameter, but in others they appeared more varicose. When these cells were found apart from vascular structures, they were counted as a separate population of NG2^+^ cells (Fig. [3](#fig03){ref-type="fig"}A). However, we also found a perivascular subtype of Pld cells that we counted as Pldv cells. Like Elu cells, Pldv cells partially enclosed vascular spaces and Pldv cell bodies protruded into those spaces (Fig. [3](#fig03){ref-type="fig"}B--**I**), but Pldv cells had multibranched processes that often obscured the vessel lumen that they bordered (Fig. [3](#fig03){ref-type="fig"}D3,E2,F2). Unlike Pld cells, that tended to be more uniformly spaced in the parenchyma, pairs of Pldv cells formed complex structures along vessel walls (Figs. [3](#fig03){ref-type="fig"}B,E,F, [4](#fig04){ref-type="fig"}). Unstained clefts in the cell body of Pldv cells appeared to be continuous with adjacent blood vessels (Fig. [3](#fig03){ref-type="fig"}C,D,**G--I**), and unstained vacuoles and narrow passages in the cytoplasm (Fig. [3](#fig03){ref-type="fig"}**G--I**) localized in some cell processes but not others. The last named features are shown in greater detail in a complex of two Pld cells in Figure [4](#fig04){ref-type="fig"}. Only two of the multiple NG2^+^ labeled processes from these cells express PDGFrβ and contain tube-like passages (single and double arrowheads) that end in large vacuolar expansions (Fig. [4](#fig04){ref-type="fig"}A,C,D; asterisks). The passages appear to be enclosed by longitudinal filaments, possibly actin filament bundles, that labeled with NG2 and PDGFrβ antibodies (Fig. [4](#fig04){ref-type="fig"}A,B3; lines). The large, central process appears to be a complex of processes from cells 1 and 2, whereas the shorter process is oriented nearly perpendicular to the longer one and arises from cell 1 alone. The clumped BrdU^+^ chromatin in both cells is indicative of late S stage in the cell cycle (Chagin et al., [@b7]) and the differential distribution of PDGFrβ suggests asymmetry in the subsequent cell divisions.

BrdU^+^/NG2^+^ cell pairs
-------------------------

Counts were made of closely spaced pairs of BrdU^+^/NG2^+^ cells that, by their appearance within the same image frame, suggested recent cell division. Cell pairs were most common in monkeys with short post-BrdU survival periods of 2 weeks or less (36% and 15% at 2 days; 15% at 2 weeks) but by 6 weeks after BrdU injection, there were fewer new cell pairs (11% and 6%). The mean and SEM for all new NG2^+^ cell pairs in the short survival monkeys was 17% ± 5% (Table[2](#tbl2){ref-type="table"}, top). In monkeys with longer post-BrdU survival times, pairs of BrdU^+^/NG2^+^ cell counts ranged from 2.5% to 10% of total BrdU^+^ cells (mean, 7% ± 1%) (Table[2](#tbl2){ref-type="table"}, bottom). BrdU^+^/NG2^+^ cell pairs were found as simple Per and Elu, cells (Fig. [2](#fig02){ref-type="fig"}F,G) and multibranched Pld and Pldv cells (Fig. [3](#fig03){ref-type="fig"}A,E).

###### 

Cell Pairs

  Monkey     BrdU\#   \% BrdU
  ---------- -------- ---------
  2 d        80       36
  2 d        46       15
  2 w        66       15
  6 w        75       11
  6 w        79       06
  mean/SEM            17 ± 5
  OR         34       09
  YC         31       06
  YR         30       10
  YRS        18       05
  YRS        40       03
  mean/SEM            07 ± 1

Percentages of BrdU^+^ cell pairs with respect to BrdU cell totals from a single IHC batch that processed sections for BrdU, NG2, and Olig2 antibodies using tissue from monkeys with single BrdU injections and short survivals after BrdU (top) and monkeys with multiple BrdU injections and long survivals after BrdU (bottom). 2 d, 2 day; 2 w, 2 week; 6 w, 6 week; OR, Older runners, YC, younger controls, YR, younger runners, YRS, younger run-stops.

Neuronal phenotypes
-------------------

We used antibodies to neuronal proteins NeuN, Cr, GABA, Cb, and DCx, in combination with BrdU antibody to look for the presence of new neurons in the precentral gyrus. Because no colabeling with DCx or Cb antibodies was seen in low-magnification scans, we discontinued use of these antibodies. BrdU^+^/Cr^+^ cells were found but most of these cells were weakly labeled compared to nearby BrdU^-^/Cr^+^ cells. Only about 25% of Cr^+^ cells had well-developed processes (Fig. [5](#fig05){ref-type="fig"}A,B) and denser Cr^+^ labeling. BrdU^+^/GABA^+^ cells were also found that were similar to Cr^+^ cells in size and juxtaposition to larger neurons (Fig. [5](#fig05){ref-type="fig"}C). BrdU^-^/Cr^+^ cells colabeled with NeuN antibody (Fig. [5](#fig05){ref-type="fig"}D) but no new Cr^+^ or GABA^+^ cells were NeuN^+^. About 7.5% (181/2400) of new cells were Cr^+^ in a sampling of 100 cells from each of 24 experimental monkeys, and almost half of these cells (48%) were found in eight run-stop monkeys that survived the longest period after multiple BrdU injections. In a second study, brain sections from five monkeys with short, post-BrdU survivals and four run-stop monkeys with 27-week, post-BrdU survivals were processed with BrdU, Cr, and NG2 antibodies. We found a comparable percentage of BrdU^+^/Cr^+^ cells (∼7.6%, *n* = 383) as in the first study. Also similar to the results in the first study, there were almost 5 times as many BrdU^+^/Cr^+^ cells in the run-stop group of monkeys. Satellite BrdU^+^/Cr^+^, BrdU^-^/Cr^+^, and BrdU^+^/GABA^+^ cells were often found in close apposition to the soma of larger NeuN^+^ neurons (Fig. [5](#fig05){ref-type="fig"}B--D) and, occasionally, we saw satellite NG2^+^ cells with unstained profiles of large pyramids (not shown) but a separate count of satellite phenotypes was not made. New NG2^+^ cells were also seen juxtaposed onto BrdU^-^/Cr^+^ cells (Fig. [5](#fig05){ref-type="fig"}F) but not BrdU^+^/Cr^+^ cells and no NG2^+^ cells colabeled with Cr antibody. In a count of monkeys from the six groups of the exercise study, we estimated about 34% (SEM ± 2%) of BrdU^+^ cells were satellite cells on NeuN^+^ neurons (Fig. [5](#fig05){ref-type="fig"}E).

![BrdU^+^ cells labeled with Cr, GABA, and glial antibodies. A: Single optical sections in the xy and xz planes through a multipolar BrdU^+^/Cr^+^ cell. B: A bipolar, BrdU^+^/Cr^+^ cell and single-labeled BrdU^+^ cell. The bipolar cell is closely apposed to the larger NeuN^+^ neuron. Inset shows the impression made by the Cr^+^ cell. C: Two BrdU^+^/GABA^+^ satellite cells juxtaposed on a larger NeuN neuron. A third, BrdU^-^/GABA^+^ cell is also seen. Note all GABA^+^ cells are immature but are comparable in size and in juxtaneuronal position to the Cr^+^ cell seen in B. D: Two BrdU^+^ neurons that are satellite cells on NeuN^+^ and NeuN^+^/Cr^+^ cells. E: Percentages of BrdU^+^ counted as neuronal satellites in a series of exercise monkeys. OC, older control; OR, older runner; ORS, older run-stop; YC, younger control; YR, younger runner; YRS, younger run-stop. F: BrdU^+^/NG2^+^ cell closely applied to a Cr^+^ cell. G: NG2 and s100β antibodies label separate populations of cells. H: NG2 and Iba1 label separate populations of cells. Scale bars = 10 μm.](cne0523-0849-f5){#fig05}

Other glial markers
-------------------

Low-magnification, confocal microscope scans were used to look for colabeling of microglial antibody Iba1 and astrocyte antibodies GFAP and s100β with NG2^+^ cells. NG2^+^ cells were morphologically distinct from astrocytes and microglia and no cells were double-labeled. (Fig. [5](#fig05){ref-type="fig"}G,H). Therefore, we discontinued use of s100β and IBa4 antibodies. The oligodendrocyte cell line protein, Olig2, was expressed in about 78% of BrdU^+^/NG2^+^ cells (SEM ± 4%; *n* = 375 cells) in one IHC batch. The granular, nuclear labeling with Olig2 antibody was easily detectable in some NeuN^+^ cells (Fig. [2](#fig02){ref-type="fig"}G) but very sparse or not detectable in others (Fig. [3](#fig03){ref-type="fig"}B). In all cases, Olig2 labeling was confined to the nucleus and no cells were Olig2^+^/NG2^-^. Except for Per cells, all other NG2^+^ cell phenotypes expressed Olig2.

Unidentified cells
------------------

BrdU^+^/NG2^+^ cells that were not multibranched and not perivascular were classified as NG2^+^ unknown cells in Tables[3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}. New cells that did not express NG2 (NG2^--^) were counted as perivascular or not perivascular. Based on morphology and cell location, we reasoned that some BrdU^+^/NG2^--^ perivascular cells were endothelial cells or mature pericytes that no longer expressed NG2. The cell group, \"BrdU^+^/NG2^--^ NOT perivascular,\" included BrdU^+^/Cr^+^ cells.

###### 

New Cell Phenotypes in Monkeys With Short Survivals After Single BrdU Injections

  A.                                                                                                              
  ------------- ----------- ----------- ----------- ----------- --------- ----------- ------------ ---- ---- ---- ----
  2 d *(121)*   43 *(52)*   5 *(6)*     18 *(22)*   28 *(34)*   1 *(1)*   6 *(6)*     94 *(114)*   48   49   23   71
  2 d *(92)*    40 *(37)*   0 *(0)*     10 *(9)*    40 *(37)*   3 *(3)*   7 *(6)*     90 *(83)*    40   43   10   80
  2 w *(109)*   48 *(52)*   6 *(7)*     21 *(23)*   8 *(9)*     5 *(5)*   13 *(14)*   83 *(91)*    54   59   28   56
  6 w *(115)*   16 *(18)*   29 *(33)*   34 *(39)*   9 *(10)*    3 *(4)*   10 *(11)*   86 *(99)*    44   48   63   24
  6 w *(119)*   22 *(26)*   13 *(16)*   34 *(41)*   6 *(7)*     3 *(3)*   19 *(23)*   74 *(88)*    35   38   48   28

  B.                                       
  ------------------------------ ---- ---- ----
  All NG2/BrdU                   83   86   89
  Per-Elu                        29   33   37
  Pldv                           9    11   14
  Pld                            21   24   28
  NG2^+^ unknown                 14   17   21
  NG2^−^ perivascular            2    3    5
  NG2^−^ NOT perivascular        9    11   14
  NG2^+^ perivascular combined   40   44   48
  All perivascular               43   47   52
  NG2^+^ Multi-branched          31   35   39
  NG2^+^ NOT Multi-branched      46   51   55

A: Percentages of BrdU^+^ cell totals for NG2^+^ and NG2^−^ cell types and cell combinations from monkeys with single BrdU injections and short survivals after BrdU. Cell counts are in parentheses and italicized. 2 d, 2 day; 2 w, 2 week; 6 w, 6 week; a, NG2^+^ unknown (not perivascular, not multi-branched); b, Per-Elu and Pldv; c, Per-Elu, Pldv, and NG2^−^ perivascular; d, Pldv and Pld; e, Per-Elu, and NG2^+^ unk. B: Estimated mean percentages and ranges of new cell phenotypes and combinations based on binomial regression modeling.

###### 

New Cell Phenotypes in Monkeys With Long Survivals After Multiple BrdU Injections

  A.                                         
  ------------------------------ ----- ----- -----
  All NG2%BrdU                   83%   85%   87%
  PerElu                         24%   27%   30%
  Pldv                           20%   23%   26%
  Pld                            25%   27%   30%
  NG2^+^ unknown                 5%    7%    8%
  NG2^−^ perivascular            3%    4%    5%
  NG2^−^ NOT perivascular        9%    11%   13%
  NG2^+^ perivascular combined   48%   51%   54%
  All perivascular               51%   54%   57%
  Multibranched                  48%   51%   54%
  NOT Multibranched              31%   34%   37%

  B.                                                                                                                                                                                                                                                                                                                                                                         
  ------------------------------ ----------------------------------- ------------------------------------- ---------------- ----------------------------------- -------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ------------------------------------- ---------
  OC *(136)*                     26 ± 8 *(35)*                       39 ± 10 *(53)*                        21 ± 8 *(28)*    6 ± 1 (8)                           3 ± 2 *(4)*    6 ± 3 *(8)*                           91 ± 3 *(124)*                        65 ± 6                                68 ± 7                                60 ± 11                               32 ± 8
  OR *(185)*                     34 ± 4 *(62)*                       19 ± 2 *(35)*                         25 ± 4 *(46)*    8 ± 4 *(14)*                        3 ± 2 *(6)*    12 ± 5 *(22)*                         85 ± 3 *(157)*                        52 ± 5                                56 ± 4                                44 ± 3                                41 ± 3
  ORS *(154)*                    32 ± 6 *(50)*                       21 ± 7 *(32)*                         21 ± 13 *(33)*   10 ± 4 *(16)*                       5 ± 1 *(8)*    10 ± 4 *(15)*                         85 ± 3 *(131)*                        53 ± 2                                58 ± 3                                42 ± 13                               43 ± 9
  YC *(84)*                      30 ± 12 *(25)*                      19 ± 8 *(16)*                         32 ± 10 *(27)*   2 ± 1 *(2)*                         5 ± 4 *(4)*    12 ± 3 *(10)*                         83 ± 2 *(70)*                         49 ± 3                                54 ± 8                                51 ± 14                               32 ± 14
  YR *(204)*                     21 ± 3 *(42)*                       30 ± 5 *(61)*                         33 ± 6 *(68)*    5 ± 2 *(10)*                        4 ± 2 *(8)*    7 ± 2 *(15)*                          89 ± 3 *(181)*                        50 ± 3                                54 ± 2                                50 ± 10                               25 ± 6
  YRS *(376)*                    24 ± 5 *(92)*                       13 ± 3 *(48)*                         31 ± 3 *(115)*   10 ± 2 *(36)*                       3 ± 2 *(10)*   20 ± 4 *(75)*                         77 ± 4 *(291)*                        37 ± 6                                40 ± 6                                37 ± 3                                34 ± 6
  Comparisons                    *P* values                                                                                                                                                                                                                                                                                                                                  
  OC - OR                                                            [\*\*](#tf4-2){ref-type="table-fn"}                                                                                                                                                                                                                               [\*](#tf4-1){ref-type="table-fn"}     --
  OC - ORS                                                           [\*](#tf4-1){ref-type="table-fn"}                                                                                                                                                                                                                                 [\*](#tf4-1){ref-type="table-fn"}     
  OC - YC                                                            [\*](#tf4-1){ref-type="table-fn"}                                                                                                                                                                                                                                                                       
  OC - YRS                                                           [\*\*](#tf4-2){ref-type="table-fn"}                                                                       [\*\*](#tf4-2){ref-type="table-fn"}   [\*\*](#tf4-2){ref-type="table-fn"}   [\*\*](#tf4-2){ref-type="table-fn"}   [\*\*](#tf4-2){ref-type="table-fn"}   [\*](#tf4-1){ref-type="table-fn"}     --
  OR - YR                                                                                                                                                                                                                                                                                                                              [\*\*](#tf4-2){ref-type="table-fn"}   --
  OR - YRS                       [\*](#tf4-1){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                           
  ORS -- YR                                                                                                                                                                                                                                                                                                                            [\*\*](#tf4-2){ref-type="table-fn"}   
  YR - YRS                                                                                                                                                                                                           [\*](#tf4-1){ref-type="table-fn"}     [\*](#tf4-1){ref-type="table-fn"}     [\*](#tf4-1){ref-type="table-fn"}     [\*\*](#tf4-2){ref-type="table-fn"}   --
  YRS -- ORS                                                                                                                                                                                                                                               [\*\*](#tf4-2){ref-type="table-fn"}   [\*\*](#tf4-2){ref-type="table-fn"}                                         
  All Run-stops v All Controls                                       [\*\*](#tf4-2){ref-type="table-fn"}                    [\*](#tf4-1){ref-type="table-fn"}                  [\*](#tf4-1){ref-type="table-fn"}     [\*](#tf4-1){ref-type="table-fn"}     [\*\*](#tf4-2){ref-type="table-fn"}   [\*\*](#tf4-2){ref-type="table-fn"}   [\*\*](#tf4-2){ref-type="table-fn"}   --
  All Runners v All Controls                                                                                                                                                                                                                                                                                                                                                 --
  All Runners v All Run-stops                                                                                                                                                  [\*\*](#tf4-2){ref-type="table-fn"}   [\*](#tf4-1){ref-type="table-fn"}     [\*](#tf4-1){ref-type="table-fn"}     [\*](#tf4-1){ref-type="table-fn"}     [\*\*](#tf4-2){ref-type="table-fn"}   --

A: Estimated mean percentages and ranges for new cell phenotypes and cell combinations based on binomial regression modeling. B: Above, mean percentages of BrdU^+^ cell totals and SEMs for NG2^+^ and NG2^−^ cell types and cell combinations from each group of experimental exercise monkeys. Cell counts are in parentheses and italicized. Below, *P* values of significant differences in paired comparisons of exercise groups. Calculated *P*-values correspond to comparing the log odds ratios resulting from binomial regression analysis.

*P* = 0.05 −0.01

*P* \> 0.01. OC, older control group; OR, older runner group; ORS, older run-stop group; YC, younger control group; YR, younger runner group; YRS, younger run-stop group; *n* = 4 except YC where *n* = 3.

Cell phenotype proportions: single injection, short survival monkeys
--------------------------------------------------------------------

The percentages of BrdU^+^ cell totals for all NG2^+^ cells, individual cell types, and cell combinations in the five monkeys that survived 2 days, 2 weeks, and 6 weeks following single BrdU injections appear in Table[3](#tbl3){ref-type="table"} and Figure [6](#fig06){ref-type="fig"}A. Per and Elu cells were counted as a single category for the analysis. The data in Table[3](#tbl3){ref-type="table"}A shows reciprocal trends in NG2^+^ cell branch morphology with respect to time after BrdU injections. Percentages of NG2^+^ cells with few or no processes (Per-Elu, NG2^+^ unknown) were high in monkeys that survived 2 days and 2 weeks and one-third to one-half lower in monkeys that survived 6 weeks, whereas the percentages of multibranched cells (Pldv, Pld) were higher in the monkeys that survived 6 weeks after single BrdU injections and much lower in monkeys that survived 2 days and 2 weeks. Furthermore, percentages of unidentified NG2^+^ cells (NG2^+^ unknown) cells were 3--6 times higher in monkeys with 2-day survivals than in monkeys with survivals of 2 or 6 weeks. The estimated means for total NG2^+^ cells and cell types appears in Table[3](#tbl3){ref-type="table"}B. About 86% of total BrdU^+^ cells counted (*n* = 556) were NG2^+^, of which 47% were all perivascular (sum of Per-Elu, Pldv, NG2^--^ perivascular). In short survival monkeys, Cr^+^ cells comprised about 10% of the category \"NG2^--^ NOT-perivascular cells.\"

![A: Estimated mean percentages, relative to BrdU^+^ cell totals, of individual and combined NG2^+^ and NG2^--^ cell types from monkeys that survived short periods after single BrdU injections. B: Estimated mean percentages of individual and combined NG2^+^ and NG2^--^ cell types from monkeys that survived long periods after multiple BrdU injections. C: Relative proportions of adult born (BrdU^+^) cell types defined morphologically and immunohistochemically. The cumulative means listed in Table[2](#tbl2){ref-type="table"} were used to construct proportionate wedges of the chart. BrdU^+^/NG2^+^ cells are represented by gray wedges. Per cells (2.5%) are shown separately from the Per-Elu group. BrdU^+^/NG2^--^ cells (perivascular, non-perivascular) appear as white wedges with a separate wedge for Cr^+^ cells (7--8%) derived from the total non-perivascular group in Table[2](#tbl2){ref-type="table"}. All adult born perivascular cells appear in wedge segments between the arrowheads. Satellite cells comprising about 34% of all BrdU^+^ cells are not shown. NG2^+^ unk: unknown, not perivascular, not multibranched new cells; NG2^--^ unk: not perivascular new cells.](cne0523-0849-f6){#fig06}

Cell phenotype proportions: multiple injection, long survival monkeys
---------------------------------------------------------------------

Estimated mean percentages of BrdU^+^ cell totals for individual cell types and cell combinations from experimental exercise monkeys with multiple BrdU injections and long post-BrdU survivals are shown in Table[4](#tbl4){ref-type="table"} and Figure [6](#fig06){ref-type="fig"}B. The estimated percentage of all NG2^+^ cells was about 85% (Table[4](#tbl4){ref-type="table"}A) as compared to 86% (Table[3](#tbl3){ref-type="table"}B) in short survival monkeys. Percentages of individual cell types overlapped upper and lower estimates between the two datasets except for Pldv and NG2^+^ unknown cells. The respective increase and decrease in percentages of these two cell types in experimental animals were attributed to maturation from simple to complex branching forms that appeared to occur around 6 weeks after BrdU injections. (Note that the mean percentage of Pldv cells from the two 6-week monkeys was 21% (Table[3](#tbl3){ref-type="table"}B), compared to a mean of 22% for Pldv cells from experimental animals (Table[4](#tbl4){ref-type="table"}A).) The higher Pldv cell percentages in long survival monkeys weighted the percentages of multibranched cells, NG2^+^ perivascular cells, and all perivascular cells in this group relative to the short survival monkeys, but the percentages of Pld cells in the two groups largely overlapped. One unseen difference in the two datasets was in the percentages of BrdU^+^/NG2^--^ cells. This cell category contained cells that were unidentified in monkeys with short post-BrdU injection survivals but in monkeys with longer survival times after BrdU, this category included Cr^+^ cells. In long survival monkeys, Cr^+^ cells made up about one-third of the total NG2^--^ nonperivascular cells and about half of these cells were counted in younger run-stop (YRS) monkeys.

Table[4](#tbl4){ref-type="table"}B shows the percentages of BrdU^+^ cell totals for individual cell types and cell combinations from each experimental exercise group. Pairwise comparisons were made between each group for each cell type and cell combination. Significant comparisons (lower part of the table) were influenced by the following outcomes. 1) Older control (OC) monkeys had the highest percentage of Pldv cells and Total NG2^+^ cells. The percentage of Pldv cells in OC group was significantly higher than the percentage of this cell type in other groups except younger runners and the high percentage of Pldv cells probably contributed to the significant difference in the combined group comparison of All controls versus All Run-stops. 2) The YRS group had the lowest percentage of Pldv cells and the lowest percentages of cells in the Total NG2^+^, All NG2^+^ perivascular, All perivascular, and NG2^+^ multibranched cell categories. The percentages of cells in these categories were significantly lower in YRS monkeys compared to YR monkeys and in All Run-stop versus All Runner monkeys, which suggested a possible effect of the postexercise sedentary period. 3) YRS monkeys had the highest percentage of BrdU^+^/NG2^-^, NOT perivascular cells, which contributed to a statistically significant difference in the comparison of this cell category between All Run-stops and All Runners and All Run-stops and Controls. 4) ORS and YRS monkeys had the highest percentages of NG2^+^ unknown cells (not multibranched, not perivascular), which contributed to a statistically significant difference in the comparison of this cell category between All Run-stops and All Controls. The last two comparisons suggest that unidentified new cells increase during the postexercise period. A significant age-related comparison of individual NG2^+^ cells types was the higher percentage of Per-Elu cells in the OR group versus the YR group, whereas the OR monkeys had a lower percentage of NG2^+^ multibranched cells. The ORS group also had a significantly higher percentage of NG2^+^ perivascular and All perivascular cell combinations compared to the YRS group. No other individual cell type comparisons were significantly different between groups and no significant differences were seen in any cell type category between all runners and all controls.

Cell type summary
-----------------

The relative proportions of adult born cell types that were morphologically and immunohistochemically identified in the present study are summarized in Fig. [6](#fig06){ref-type="fig"}C using data from Table[4](#tbl4){ref-type="table"}A. A little more than half (∼54%) of BrdU^+^ cells are perivascular including probable pericytes, two NG2^+^ cell types (Elu, Pldv) that have not been described previously, and NG2^--^ perivascular cells that include possible endothelial cells and mature pericytes. We estimated that about 2.5% (*n* = 722, SEM \<1%) of BrdU cells from three IHC batches were Per-type cells. Calretinin-labeled BrdU^+^ cells were separated from other NG2^--^ nonperivascular cells. An estimated 34% of BrdU cells are neuronal satellite cells that are not represented in the chart.

Discussion
==========

Perivascular progenitor cells
-----------------------------

The major finding of this study is that nearly half of BrdU^+^/NG2^+^ cells are structurally and immunohistochemically associated with blood vessels in the motor cortex of adult macaque monkeys. This is the largest group of BrdU^+^/NG2^+^ cells that comprise 86% of adult born cells. Another 3--4% of BrdU^+^/NG2^--^ cells were found in and on vessel walls and probably included some endothelial and mature pericytes cells that do not label with NG2 antibody. Therefore, during the post-BrdU administration time periods that we studied, up to 54% of new cells were perivascular in monkeys that survived the longest periods after BrdU injections.

The perivascular niche where NG2^+^ perivascular cells are found is a region of local cell proliferation, differentiation, and remodeling in the brain and other tissues (Diaz-Flores et al., [@b10]; Dore-Duffy and Cleary, [@b13]; Paul et al., [@b46]). In the brain, cell signaling between endothelial cells and nearby cells of the parenchyma has been linked to neurogenesis in the hippocampus of rats (Palmer et al., [@b45]), oligodendrocyte-induced vascular remodeling in the injured mouse corpus callosum (Pham et al., [@b49]), and pericyte activity during angiogenic responses to injury (Diaz-Flores et al., [@b10]; Goritz et al., [@b19]) or hypoxia in mice (Dore-Duffy and LaManna, [@b14]). In particular, PDGF-B/PDGFrβ signaling between endothelial cells and pericytes plays a major role in developmental angiogenesis (Ozerdem et al., [@b44]) and maintenance of adult microvasculature (Bell et al., [@b2]). In the present study we show examples of Per, Elu, and Pldv cells labeled with PDGFrβ antibody along endothelial walls like that shown by Ozerdem et al. ([@b44]) and Bell et al. ([@b2]). We also found PDGFrβ antibody expression in selected processes of Pld cells that coincided with the formation of tube-like passages by cytoskeletal filaments. It is quite possible that some of these cytoskeletal filaments are actin filament bundles that colocalize and interact with NG2 to effect cytoskeletal rearrangements such as those that promote motility of cells (Fang et al., [@b17]) and cell processes (Haberlandt et al., [@b20]). Actin, NG2, and PDGFrβ^+^ also colocalize in pericytes of the retina and choroid (Trost et al., [@b61]) and in mobilized \"A\" type pericytes of the injured spinal cord (Goritz et al., [@b19]). The long tube-like passages in Pld cells also resemble the PDGFrβ-enriched tubes of embryonic pericytes (Ozerdem et al., [@b44]; Virgintino et al., [@b63]) that serve as prevascular scaffolding for later endothelial cell investment. The similarities to pericytes in appearance suggest the possibility that some Elu and Pldv cells might be incorporated into vessel walls at small vessel branch points in the presence of existing endothelial cells or, in the case of Pld cells with tube-like passages, might provide a prevascular framework for endothelial cell wall formation. These two models of vessel formation would be expected to yield vessels of different form and dynamics.

NG2 cell maturation
-------------------

The possibility that some perivascular NG2^+^ cells might have pericyte-like functions or even become pericytes does not conflict with the idea that most NG2^+^ cells are oligodendrocyte precursor cells (Dawson et al., [@b8]; Dimou et al., [@b11]; Kang et al., [@b26]; Simon et al., [@b55]; Hughes et al., [@b24]). We made several observations that support this idea. First, a large percentage of NG2^+^ cells (78%) colabeled with Olig2, a transcription protein vital for maturation of oligodendrocytes (Ligon et al., [@b39]). All BrdU^+^/NG2^+^ cell types, except for Per cells, expressed Olig 2. Second, although we did not do cell counts, we found no evidence that BrdU^+^/NG2^+^ cells colabel with astrocyte or microglial markers, a finding that agrees with other reports (Komitova et al., [@b32]; Kang et al., [@b26]; Simon et al., [@b55]). Third, we estimated that about 34% of all NG2^-^/BrdU^+^ cells were satellite cells on the cell bodies of NeuN^+^ and Cr^+^ neurons, about the same percentage of satellite cells that Koketsu et al. ([@b30]) reported in a young adult *M. fascicularis* (37.4%) and a juvenile *M. fuscata* (35.7%). As noted in the Results, some satellite cells are interneurons. Astrocytes and microglial satellite cells are also known to occur but most satellite cells in the CNS are a type of oligodendrocyte (Rakic, [@b52]; Peters et al., [@b48]; Takasaki et al., [@b58]). Because oligodendrocytes lose NG2^+^ antigenicity with the development of myelin proteins (Levine et al., [@b38]; Takasaki et al., [@b58]), it is likely that some BrdU^+^/NG2^--^ satellite cells that we found are mature oligodendrocytes.

The analysis of NG2^+^ cell type percentages in short survival monkeys also suggested a developmental trend from simple to multibranched NG2^+^ forms that has been shown to precede the maturation of premyelinating oligodendrocytes (Trapp et al., [@b60]).

There were high percentages of unbranched or simple-branched cells (Per-Elu and NG2^+^ unknown cells) and low percentages of multibranched cells (Pld, Pldv) at 2 days and 2 weeks after BrdU administration that changed to low percentages of unbranched cells and high percentages of multibranched cells at 6 weeks post-BrdU. The average percentage NG2^+^ multibranched cells from two, 6-week monkeys (55%; Table[3](#tbl3){ref-type="table"}B) was just outside the upper estimate of multibranched cells in exercise monkeys that survived 15 and 27 weeks after initial BrdU injections (Table[4](#tbl4){ref-type="table"}A). A similar developmental trend was seen in the appearance of closely paired BrdU^+^ cells. Close pairing of BrdU^+^ cells is a probable indicator of cell origins within the neocortex as apposed to migration from subventricular sources (Dayer et al., [@b9]). Our data suggests a decrease in BrdU^+^/NG2^+^ cell proliferation from highest percentages of cell pairs at 2 days (36%) and 2 weeks (15%) after single BrdU injections to lower percentages of cell pairs (11% and 6%) at 6 weeks after BrdU administration. The BrdU^+^/NG2^+^ cell percentages for 6-week monkeys largely overlapped the range of percentages from the monkeys with longer survivals after BrdU injections (2.5--10%). The 6-week period after an initial population of NG2^+^ cells was labeled might indicate the beginning of a second cycle for these cells in the monkey motor cortex. It is known that, in mice, NG2^+^ cells have long cell cycles (Simon et al., [@b55]; Hughes et al., [@b24]) and that proliferation of these cells decreases by two-thirds after the first division (Hughes et al., [@b24]). The cell cycle length in mice was calculated at 37 days in one study (Simon et al., [@b55]) and averaged at 18 days (range 5--40 days) in another (Hughes et al., [@b24]). However, a longer cell cycle for NG2^+^ cells in monkeys might be expected based on our earlier findings that maturation times for granule cells in the monkey hippocampus were as much as 6 times longer than maturation times for these cells in rodents (Kohler et al., [@b29]).

Overall, the mean percentages of BrdU^+^/NG2^+^ cells from both short and long post-BrdU survival groups is about 86% of total BrdU^+^ cells. This percentage is higher than the estimated 74% of adult born cells that are NG2^+^ in the rat cerebral cortex (Dawson et al., [@b8]) and 80% in the mouse neocortex (Simon et al., [@b55]). Because some NG2^+^ cells lose their antigenicity as they mature and others die off, the constancy of NG2^+^ cells in the adult born cell population over the timepoints that we studied indicates that these cells continue to proliferate in proportion to the depletion of their numbers by cell death and maturation. The appearance of NG2^+^ cell pairs in monkeys that survived 27 weeks after BrdU injections is evidence of their continued proliferation. Cell fate studies have shown that NG2^+^ cells are generated continuously in the cerebral cortex of adult mice (Kang et al., [@b26]; Simon et al., [@b55]) throughout time periods as long as 70 days (Simon et al., [@b55]).

Some comparisons to NG2^+^ studies in rodents
---------------------------------------------

The perivascular locations and different morphologies of NG2 cells that we see in the monkey contrast with the commonly held idea, based largely on studies in mice, that 95% of NG2 cells are polydendrocytes (Nishiyama et al., [@b42]). In our study, the estimated total of all polydendrocytes (all multibranched NG2^+^ cells in Table[3](#tbl3){ref-type="table"}A) was 51%, of which 23% were polydendritic perivascular cells. It has also been reported that \"a vast majority\" of new cells in the visual cortex and about 74.2% of new cells in the amygdala of adult mice coexpressed NG2 and astroglial marker s-100β (Ehninger 2011). We found no colabeling of NG2^+^ cells with either astroglia marker s-100β or GFAP or with microglia marker Iba-1.

NG2 is also expressed in mesenchymal cells, including macrophages that are excluded from the brain in normal circumstances and so were not studied herein, and vascular mural cells that include smooth muscle cells and pericytes. Both cell types have processes confined to vessel walls but pericytes lie closest to the endothelial cells, are separated from them and other cells by a basement membrane (Krueger and Bechmann, [@b35]; Dore-Duffy and Cleary, [@b13]), and label specifically with PDGFrβ antibody in mice (Winkler et al., [@b65]). We used these criteria (except for ultrastructural identification of the basement membrane) to estimate NG2^+^ pericytes at 2.5% of NG2^+^ cells. In transgenic mice, an estimated 1.5% of NG2^+^ glial progenitor cells were pericytes (Kang et al., [@b26]).

Elu cells made up about a quarter of the NG2^+^ perivascular cells. These cells, which displayed prominent nuclei and cell bodies and few cell processes that they extended into the brain parenchyma, have not been described in mice, although pericytes with processes were seen in the developing rat optic nerve (Quimby and Fern, [@b51]) and cells with radial processes have been identified as pericytes by other criteria (fig. [2](#fig02){ref-type="fig"}b, Hughes et al., [@b24]).

There are several possible reasons why the perivascular NG2 cell types that we identified have not been described previously in rodents. First, most studies have concentrated on the polydendritic NG2 progenitor cells that differentiate into oligodendrocytes (Komitova et al., [@b33]; Kang et al., [@b26]) and deliberately excluded perivascular NG2 cells from consideration (Komitova et al., [@b33]; Simon et al., [@b55]). Also, most studies have imaged these cells at relatively low confocal magnifications as compared to the images presented in the present report and, as seen in Figure [3](#fig03){ref-type="fig"}D--F, vessels associated with polydendritic cells were often obscured by the cell branches from these cells, particularly in images generated from confocal projection stacks. Furthermore, vessels in the parenchyma might not be seen unless specific methods are used to detect them (Fig. [2](#fig02){ref-type="fig"}E). Finally, NG2 progenitor cells in mice are relatively smaller than in monkeys and the cytoskeletal features that we describe may be less obvious in smaller cells.

Immature calretinin interneurons
--------------------------------

We found a consistent proportion (∼7.5%) of new Cr^+^ cells (but not calbindin cells) in new cell counts from tissue prepared in two separate IHC batches. BrdU^+^/GABA^+^ cells were also found but not counted. The discovery of these cells was surprising because we found no evidence of DCx labeling for immature neurons in the motor cortex and Koketsu et al. ([@b31]) found only 2/30,000 DCx^+^ neocortical cells in their study. The actual number of new Cr^+^ cells/monkey was quite small. In a new cell frequency count of 24 long survival monkeys (100 cells/monkey/3 sections), four monkeys had no new Cr^+^ cells and nine had 1--3 new Cr^+^ cells. Furthermore, in contrast to robust labeling and well-stained processes in established BrdU^-^/Cr^+^ cells, most BrdU^+^/Cr^+^ cells were weakly labeled cell soma and only about 25% of new Cr^+^ cells had bipolar or simply branched multipolar processes resembling mature calretinin interneurons.

Expression of Cr developed late but appeared to increase over time. The highest percentage of BrdU^+^/Cr^+^ cells were found in monkeys that survived 27 weeks after the first of 10 weekly injections of BrdU. We considered that new Cr^+^ cells in the motor cortex might have a prolonged maturation comparable to the hippocampal granule cells that we described in these same experimental monkeys (Kohler et al., [@b29]). However, we rejected this idea because even though granule cell maturation was prolonged, about 40% of granule cells were NeuN^+^ by the end of 27 weeks. Therefore, we conclude that it is unlikely that BrdU^+^/Cr^+^ cells that we find in the motor cortex reach maturity and become functionally connected. This conclusion is in agreement with earlier ones (Rakic, [@b52]; Kornack and Rakic, [@b34]; Koketsu et al., [@b30]), and with the observation, based on ^14^C birth dating of neocortical neurons in humans, that neuron birthdates in all cerebral lobes matched the age of the individual and no neurons of younger ages were detected (Bhardwaj et al., [@b3]).

It is possible that new, immature Cr^+^ cells might have short-lived, trophic functions in the adult motor cortex. This might occur nonsynaptically, as in the secretion of reelin protein into perineuronal nets by a small percentage of calretinin interneurons (Pesold et al., [@b47]) or synaptically, because GABAergic neurons form functional synapses before reaching maturity (Verhage et al., [@b62]; Le Magueresse and Monyer, [@b36]). Excitatory GABAergic synapses on gray matter NG2^+^ cells increase BDNF production in NG2^+^ cells (Tanaka et al., [@b59]) and increase motility of NG2 cell processes (Haberlandt et al., [@b20]). Although we were unable to show evidence for synaptic contact between NG2^+^ cells and immature BrdU^+^/Cr^+^ cells, we did find close apposition between mature Cr^+^ and new NG2^+^ cells (Fig. [6](#fig06){ref-type="fig"}F) that supports the idea of synaptic communication between these cell types.

Technical considerations
------------------------

We used data from two studies that were different with respect to the amount and frequency of BrdU injections, the species types, and the experimental conditions. However, the mean percentages of all new NG2^+^ cells were nearly the same and the proportions of cell phenotypes were also similar for both datasets. Therefore, we concluded that differences in experimental methods did not significantly impact the data analysis. We reached the same conclusion in a separate study of granule cell maturation in the hippocampus using these same monkeys (Kohler et al., [@b29]).

There was considerable variability between individual animals in the same animal groupings in some BrdU^+^/NG2^+^ and BrdU^+^/Cr^+^ cell counts. Variability in counts of cells labeled with BrdU^+^ and colabels was reported previously (Dayer et al., [@b9]). In part, variability in BrdU labeling might be the result of the method itself. It is known that BrdU effects the migration, cell numbers, and possibly cell survival (Breunig et al., [@b4]; Duque and Rakic, [@b15]). Furthermore, NG2^+^ cells, the largest group of adult born cells, might have been more susceptible to negative effects of BrdU due to long maturation times for these cells. However, as noted, we found similar proportions of BrdU^+^ labeled cells in the two study groups of monkeys even though cells labeled in monkeys with multiple-injections and longer, post-BrdU survivals were most likely to be vulnerable to the negative effects of BrdU exposure.

We found the expression of PDGFrβ in all NG2^+^cells rather than being limited to pericytes, as Winkler et al. ([@b65]) reported. However, because we find the same localization of PDGFrβ in pericytes along the vessel lumen, as seen in pericytes of adult mice (Winkler et al., [@b65]) and human embryonic tissue (Virgintino et al., [@b63]), we conclude that expression of PDGFrβ in other, non-pericyte NG2^+^ cells is meaningful and that PDGFrβ expression in monkeys is different than it is in mice. We emphasize that, although PDGFrβ antibody labeling aids in the recognition of NG2^+^ perivascular cells, classification of these cell types does not depend on use of this antibody.

Effect of exercise on NG2 cells
-------------------------------

We anticipated that exercise might generate an increase in the proportion of new NG2^+^ perivascular cells because exercise increased vascular volume fraction in the neostriatum (Kohler et al., [@b28]) and in the motor cortex (Rhyu et al., [@b53]) of older runner monkeys from the same experimental monkeys used in the present study. However, we did not see proportional increases in either BrdU^+^/NG2^+^ (pericytes, Elu, and Pldv cells) or in BrdU^+^/NG2^--^ perivascular cells (including endothelial cells) in any exercise group. We reasoned that this might be because new, vessel-forming cells were generated during the study\'s 9-week, exercise training period prior to BrdU injections, and that after a peak of new vessel-forming cell production, the relative proportions of these new cell phenotypes in exercise monkeys became comparable to new cell phenotypes in sedentary controls and short-survival monkeys. Furthermore, the exercise monkeys in our study rested 5 weeks and 12 weeks before histology, whereas an effect of exercise on NG2^+^ cells in mice was detected immediately after exercise cessation (Simon et al., [@b55]). A stereological cell density study of new cell phenotypes might have detected differences due to exercise but such an analysis was not technically feasible because tissue pretreatment for BrdU immunohistochemistry disrupts generalized stains for all cell nuclei.

A percentage decrease in the Pldv cell type and percentage increases in BrdU^+^/NG2^+^ unknown cells (not perivascular / not multibranched) and non-perivascular BrdU^+^/NG2^--^ cells were seen in the run-stop monkey group compared to control and runner groups, respectively. The decrease in percentages of Pldv cells might have resulted from cell death, loss of NG2 expression as these cells matured, or both, but the significant increase in the proportion of new, unidentified NG2^--^ and NG2^+^ cells in run-stop monkeys is consistent with the idea that Pldv cells mature and differentiate into another form. In mice, for example, percentages of NG2^+^ cells were dramatically lower and percentages of mature oligodendrocytes were higher in exercised versus nonexercised subjects (Simon et al., [@b55]). In our study, the postexercise period changes might be related to vascular remodeling that occurred after exercise (Kohler et al., [@b28]; Rhyu et al., [@b53]). It should be noted that because run-stop monkeys survived the longest period after initial BrdU injections, the length of post-BrdU survival is another factor that might have influenced the proportions of cell phenotypes in run-stop monkey groups.

An interaction of monkey age with exercise was also suggested by the results of our experiment. Older runners had higher percentages of Per-Elu cells and lower percentages of multibranched forms compared to their counterparts, and older run-stop monkeys had higher percentages of combined perivascular phenotypes than younger run-stop monkeys. These differences might indicate a relatively slower maturation in older monkeys from simple, perivascular NG2^+^ cells to more complex polydendritic cells in the brain parenchyma.

In the present study, we have shown that approximately half of newly generated NG2^+^ cells in the adult monkey motor cortex are two cell types, Elu and Pldv cells, that share anatomical and immunohistochemical features with NG2^+^ pericytes and might share functional properties as well. The proportions of both cells types, but Pldv cells in particular, were responsive to variables of the exercise experiment, although a direct relationship to exercise could not be demonstrated.
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